9 results
Primary ObjectiveTo determine whether GWP42003-P affects the pharmacokinetic (PK) profile of stiripentol (STP) or valproate (VPA).Secondary Objective(s)To assess the safety and tolerability of GWP42003-P in the presence of STP or VPA.
Determine effect of asprin and simvastatin on platelet and monocyte gene expression in vivo.
To study the effect of 80 mg aspirin intake at bedtime compared with 80 mg aspirin intake on awakening on circadian rhythm of platelet function in healthy subjects.
Primary Objective: To determine whether GWP42003-P affects the pharmacokinetic (PK) profile of stiripentol (STP) or valproate (VPA).Secondary Objective: To assess the safety and tolerability of GWP42003-P in the presence of STP or VPA.To assess…
Dual Primary Objectives:* To determine if apixaban is noninferior to VKA (INR target range 2.0-3.0) on the combined endpoint of ISTHmajor or clinically relevant non-major bleeding in patients with NVAF who develop ACS or undergo PCI withplanned…
Primary objectives:*To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces therisk of a composite of myocardial infarction, stroke, or cardiovascular death in subjects with…
To determine if the use of apixaban in patients with SCAF will reduce the incidence of stroke and systemic embolism compared to aspirin.
The study aims to evaluate a modified Anti-Platelet Therapy, when associated with low-dose rapamycin DES Firehawk in Acute Myocardial Infarction Patients treated with complete revascularization strategy.. The modified antiplatelet therapy consists…
The main objective is to assess the safety and feasibility of the direct omission of aspirin after PPCI with the continuation of ticagrelor monotherapy in STEMI patients. The secondary objectives are to demonstrate the reduction of IMH and infarct…